Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06160778
Other study ID # 23-0952
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 14, 2024
Est. completion date December 2029

Study information

Verified date November 2023
Source University of Calgary
Contact Mohamed M Eltorki, MBChB, MSc
Phone +1403-955-7723
Email mmeltork@ucalgary.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Appendicitis is a common condition in children 6-17 years of age, and the top reason for emergency surgery in Canada. Children with appendicitis can have very bad pain in their belly. Children often need pain medications given to them through a needle in their arm called an intravenous (IV). The most common IV pain medication is a type of opioid called morphine. We know that opioids work well to improve pain, but there are risks and side effects when taking them. There are non-opioid medications that doctors can give to patients, like ketorolac. Ketorolac helps decrease inflammation and pain and has fewer side effects when a patient takes it for a short period of time. Our past and present overuse of opioids, driven by an unproven assumption that opioids work best for pain, resulted in an Opioid Crisis and doctors are now looking for alternatives. To do this, we need to prove that there are other options to treat children's pain that are just as good as opioids, with less side effects. The goal of our study is to discover if school aged children who arrive at the emergency department with belly pain, improve just as much with ketorolac as they do with morphine. To answer this question, we will need a very large number of patients in a study that includes several hospitals across Canada. With a flip of a coin, each participant will either get a single dose of morphine or a single dose of ketorolac. To make sure that our pain assessment is impartial, no one will know which medicine the child received except the pharmacist who prepared the medicine.


Description:

Background: Appendicitis, the most common surgical diagnosis in Canadian children aged 6-17 years, accounts for ~8000 admissions annually. Despite an ongoing opioid crisis, prescription narcotics remain a mainstay analgesic for children with suspected appendicitis. Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), which has a safer adverse event (AE) profile than opioids, is commonly used in emergency departments (EDs) for adults; however, use in children is considered off label due to a lack of randomized trials in this patient population. We propose a multi-centre clinical trial to address this knowledge gap,informed by our team's successful pilot trial. Specific Aim 1: To determine if administering intravenous (IV) ketorolac is non inferior to IV morphine in reducing mean pain scores in children with suspected appendicitis. Hypothesis: IV ketorolac will be non-inferior to IV morphine Specific Aim 2: To determine between group differences in rates of AEs. Hypothesis: IV ketorolac will be associated with less AEs than IV morphine. Design: A randomized quadruple blind (participant, clinician, outcome assessor, investigator) parallel group double-dummy trial in 4 Canadian pediatric EDs. Eligible patients will be 6-17 years with 5-days of moderate-severe pain (vNRS ≥5 ) being investigated for suspected appendicitis, with intravenous (IV) access, will be randomized to either: 1. IV ketorolac 0.5 mg/kg up to 30 mg (intervention) + IV morphine placebo (normal saline), or 2. IV morphine 0.1 mg/kg up to 5 mg (active control) + IV ketorolac placebo (normal saline). Primary outcome: Between-group mean difference in pain on the vNRS at 60 minutes following administration. Safety outcome: Proportion of children experiencing AEs related to study drug administration. Secondary Outcomes: Between-group differences: (1) pain relief as measured on vNRS at 30, 90 and 120 minutes and at 6-8 hours; (2) proportion who achieves a 2-point vNRS (minimal important difference) pain score reduction at 60 and 120 minutes; (3) proportion of patients who change their baseline pain category (vNRS: mild 0-3, moderate 4-6, severe ≥7) at each time point; (4) time to effective analgesia as measured by the time when vNRS of <3 is achieved (5) proportion of patients requiring additional analgesia; (6) total opioids administered (i.e., morphine equivalent mg/kg within 8 hours of treatment); (7) frequency of specific types of AEs (e.g., dizziness); (8) frequency of delayed appendicitis diagnosis; and (9) Ramsay Sedation Score at 30, 60, 90 and 120 minutes. Sample size:With a non-inferiority margin of 1.0 (50% of the minimal important difference), 600 participants would give a power of 0.9 (1- β) to establish non-inferiority of ketorolac vs. morphine (significance level α = 0.05).


Recruitment information / eligibility

Status Recruiting
Enrollment 495
Est. completion date December 2029
Est. primary completion date January 2029
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria: 1. Age 6 to 17 years 2. Abdominal pain =5 days duration 3. Acute abdominal pain that is being investigated (suspected) by the clinical team for appendicitis 4. Patient with IV cannula in situ or ordered 5. Currently experiencing moderate to severe abdominal pain at rest or with movement: self-reported pain score =5 using the verbal Numerical Rating Scale Exclusion Criteria: 1. Previous enrollment in the trial 2. NSAID use within 3 hours and/or opioid use within 1 to 2 hours (1 hour post-IV or intra-nasal fentanyl and 2 hours post IV morphine). 3. Children who need immediate resuscitation, are hemodynamically unstable as deemed by the clinical team or have a Canadian Triage Assessment Score of 1 4. Significant caregiver and/or child cognitive impairment precluding the ability to complete study questions. 5. Chronic pain requiring daily analgesic use: confounding as response to analgesics maybe altered. 6. History of severe undiagnosed gastrointestinal bleeding requiring medical intervention, peptic or duodenal ulcer disease or inflammatory bowel disease, coagulation disorders, prior cerebrovascular bleeding, known arterio-vascular malformations. History of minor gastrointestinal bleeding from conditions such as resolved fissures, polyps or allergic colitis will not exclude patients from participating. 7. History of chronic and active interstitial kidney disease 8. History of chronic and active hepatocellular disease: ketorolac is metabolized by the liver. 9. Known or suspected pregnancy at the time of enrollment or breastfeeding females 10. Known hypersensitivity to NSAIDs or opioids. 11. Absence of a parent/guardian for children who are <16 years of age if they are not a mature minor. 12. Inability to obtain consent due to a language barrier and the absence of language translator in person or by a phone translation service available in the ED.

Study Design


Intervention

Drug:
Ketorolac Tromethamine
Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
Morphine Sulfate
Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
normal saline
Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
Normal saline
Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.

Locations

Country Name City State
Canada Alberta Children's Hospital Emergency Department Calgary Alberta

Sponsors (2)

Lead Sponsor Collaborator
University of Calgary Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Appendix visualization on ultrasound proportion of participants who had the appendix visualized on ultrasound post-randomization and up to 8 hours post-intervention.
Primary Pain relief as measured on the verbal numerical rating scale Between group mean differences in pain as measured on an 11-point verbal Numerical Rating Scale (0 is no pain and 10 is worst pain ever) 60 minutes post drug administration
Secondary Pain relief as measured on the verbal numerical rating scale Between group mean differences in pain as measured on an 11-point verbal 30 minutes post drug administration
Secondary Pain relief as measured on the verbal numerical rating scale Between group mean differences in pain as measured on an 11-point verbal 90 minutes post drug administration
Secondary Pain relief as measured on the verbal numerical rating scale Between group mean differences in pain as measured on an 11-point verbal 120 minutes post drug administration
Secondary Pain relief as measured on the verbal numerical rating scale Between group mean differences in pain as measured on an 11-point verbal 6 hours post drug administration
Secondary Pain relief as measured on the verbal numerical rating scale during the ultrasound diagnostic score from 0-10 on verbal numerical rating scale up to 6 hours post drug administration
Secondary Proportion who achieve the minimal important difference for pain relief Proportion of participants who achieves the 2-point verbal Numerical Rating Scale minimal important difference pain score reduction 60 minutes post drug administration
Secondary Proportion who achieve the minimal important difference for pain relief Proportion of participants who achieves the 2-point verbal Numerical Rating Scale minimal important difference pain score reduction 120 minutes post drug administration
Secondary Change in baseline pain category Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) 30 minutes post drug administration
Secondary Change in baseline pain category Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) 60 minutes post drug administration
Secondary Change in baseline pain category Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) 90 minutes post drug administration
Secondary Change in baseline pain category Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) 120 minutes post drug administration
Secondary Change in baseline pain category Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) 6 hours post drug administration
Secondary Time to effective analgesia Duration of time from time of drug administration to time at which a verbal Numerical Rating Scale =3 is achieved. up to 6 hours post drug administration
Secondary Additional analgesia requirment Proportion of participants requiring any additional analgesia in each trial arm up to 6 hours post drug administration
Secondary Total opioids administered total morphine-equivalent mg/kg administered for all trial participants up to 8 hours post drug administration
Secondary Ramsay sedation score Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) 30 minutes post drug administration
Secondary Ramsay sedation score Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) 60 minutes post drug administration
Secondary Ramsay sedation score Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) 90 minutes post drug administration
Secondary Ramsay sedation score Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) 120 minutes post drug administration
Secondary Adverse events per participant Frequency of specific adverse event occurrence per participant enrolled up to 6 hours post drug administration
Secondary Frequency of each specific adverse event Frequency of each specific adverse event occurrence up to 6 hours post drug administration
See also
  Status Clinical Trial Phase
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT03825549 - A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing N/A
Completed NCT05995912 - Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain Phase 2
Recruiting NCT05589246 - Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure N/A
Recruiting NCT05572190 - Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects Phase 1
Terminated NCT04716413 - Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment Phase 4
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Not yet recruiting NCT06317844 - Examination of Psychological and Physiological Pathways Linking Gratitude and Pain N/A
Withdrawn NCT02957097 - Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures Phase 4
Terminated NCT02599870 - Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures N/A
Completed NCT02565342 - Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery Phase 4
Completed NCT02984098 - 40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose Phase 4
Completed NCT02380989 - Integrative Ayurveda Healing Relieves Minor Sports Injury Pain Phase 2
Completed NCT03107338 - Preventive Treatment of Pain After Dental Implant Surgery Phase 4
Completed NCT02489630 - Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department Phase 4
Completed NCT02817477 - Intranasal Ketamine for Acute Traumatic Pain Phase 4